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ABSTRACT
The therapeutic strategies against acute myeloid leukemia (AML) have hardly 
been modified over four decades. Although resulting in a favorable outcome in young 
patients, older individuals, the most affected population, do not respond adequately 
to therapy. Intriguingly, the mechanisms responsible for AML cells chemoresistance/
susceptibility are still elusive. Mounting evidence has shed light on the relevance 
of proteolytic systems (autophagy and ubiquitin-proteasome system, UPS), as 
well as the AMPK pathway, in AML biology and treatment, but their exact role is 
still controversial. Herein, two AML cell lines (HL-60 and KG-1) were exposed to 
conventional chemotherapeutic agents (cytarabine and/or doxorubicin) to assess the 
relevance of autophagy and UPS on AML cells’ response to antileukemia drugs. Our 
results clearly showed that the antileukemia agents target both proteolytic systems 
and the AMPK pathway. Doxorubicin enhanced UPS activity while drugs’ combination 
blocked autophagy specifically on HL-60 cells. In contrast, KG-1 cells responded in 
a more subtle manner to the drugs tested consistent with the higher UPS activity of 
these cells. In addition, the data demonstrates that autophagy may play a protective 
role depending on AML subtype. Specific modulators of autophagy and UPS are, 
therefore, promising targets for combining with standard therapeutic interventions 
in some AML subtypes.
INTRODUCTION
Acute myeloid leukemia (AML) is a highly 
heterogeneous clonal disorder comprising the most 
common acute leukemias in adults [1-3]. This disease 
is characterized by an impairment in myeloid cellular 
differentiation with accumulation of immature myeloid 
progenitor cells in the bone marrow [1-3]. Hence, AML 
heterogeneity is reflected by the diversity of myeloid 
precursors susceptible to malignant transformation. 
To date, AML therapeutic schemes result in 
favorable outcomes for young patients but, among old 
individuals have limited application, commonly due to 
the high toxicity [4, 5]. Of note, despite the efforts to 
understand AML and the considerable progress in the 
therapy, this disorder is still fatal to two-thirds of young 
adults and 90 % of older adults that develop the disease 
[6]. Thus, the elucidation of the mechanism(s) underlying 
leukemia cell’s response to chemotherapy is of utmost 
importance for the development of new strategies, 
targeting specific molecular alterations that perturb AML 
cell’s survival pathways.
The conventional therapy for AML patients during 
induction relies mainly on high doses of cytarabine in 
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combination with an anthracycline, such as doxorubicin 
[7]. Both drugs induce a DNA damage response [8, 9] 
that once activated may lead to LKB1 (Liver kinase B1) 
and AMPK (AMP-activated protein kinase) activation 
[10-12]. The LKB1-AMPK pathway is a key sensor of 
the cellular energy status that is also responsible for the 
activation of critical survival mechanisms. This pathway 
has been implicated in cancer cell biology [13] mainly as 
a tumor suppressor axis [14-19]. In hematopoietic cells, 
LKB1-AMPK has been demonstrated to be critical for 
the maintenance of energy homeostasis [20]. Therefore, 
its modulation is viewed as a promising novel treatment 
option for some types of hematological malignancies 
[13, 14, 20, 21]. Interestingly, LKB1-AMPK is also 
involved in the regulation of protein degradation through 
direct and indirect mechanism affecting the two main 
proteolytic systems, ubiquitin-proteasome system (UPS) 
and macroautophagy (hereafter called autophagy) [22, 
23]. The relevance of both proteolytic systems on cancer 
biology and particularly on hematological malignancies 
has been widely recognized [24-27]. Inhibition of UPS is 
already an attractive target for therapeutic interventions in 
different cancers including hematological malignancies. 
Bortezomib, a reversible inhibitor of the chymotrypsin-like 
activity of UPS, was already approved for the treatment 
of relapsed and refractory multiple myeloma and mantle 
cell lymphoma [28-30]. Although it has been shown that 
AML cells are more susceptible to UPS inhibition than 
non-neoplastic cells, their response is dependent on the 
AML subtype [31]. 
Importantly, autophagy may act as a “double-edged 
sword” in cancer [32]. In early tumorigenesis, it seems to 
be cancer preventing, however, in an established tumor, 
autophagy might help cancer cells to survive under 
stress. Under prolonged cytotoxic treatments, autophagy 
enhancement may act as a cancer resistance mechanism 
[33] and can be activated in response to DNA damaging 
agents, counteracting their action by avoiding cell death 
[26]. Particularly in AML chemotherapy, autophagy 
was described as reducing the activity of daunorubicin, 
obatoclax and vitamin D3 [34-36]. Furthermore, recent 
evidence suggests that autophagy acts as a pro-survival 
signal in t(8;21) AML cells [37] and, in accordance, 
a dual inhibition of mTORC1 and mTORC2 leads to 
an autophagy induction with consequent increase of 
AML cells survival [38]. In contrast, AZD8055, a dual 
inhibitor of mTORC1 and mTORC2 and a strong inducer 
of autophagy, decreases AML blast cell proliferation 
suggesting that autophagy might be contributing for 
cell death [39]. In agreement, the reduction of TRAF6 
protein, promoted by bortezomib or protein knockdown, 
is associated to autophagy induction and subsequently 
with apoptosis of AML cells [40]. Therefore, although the 
autophagic process is emerging as a crucial player and a 
promising therapeutic target in AML [26], its exact role is 
still controversial. 
Autophagy has also been shown to be regulated by 
the LKB1-AMPK pathway. This energy sensing pathway 
is known to be involved in complex interplays with 
mTORC1 and both have been suggested to have opposite 
effects on the regulation of this catabolic process [41].
Clinical trials using autophagy and UPS 
inhibitors for the treatment of different hematological 
malignancies are already ongoing, however, the results 
are still inconclusive and further investigation is required 
(reviewed in [42]).
Given the still controversial role of UPS, autophagy 
and AMPK pathway on survival/death of AML blasts, 
this work focused on evaluating the relevance of these 
processes on AML cells’ response to anti-leukemia agents. 
The results obtained with two AML cell lines highlighted 
the heterogeneous and specific nature of the different AML 
subtypes, in what concerns the relevance of AMPK and 
the proteolytic systems in response to chemotherapeutic 
agents. Chemotherapy regime promotes in HL-60 cells 
an increase of UPS activity that leads to extensive 
AMPK degradation, which among others effects, results 
in autophagy inhibition. In KG-1 cells these effects are 
discreet and most probably related to the specific features 
displayed by these cells such as high UPS activity. 
Altogether, the results show that these survival pathways 
are promising targets for therapeutic intervention in some 
AML subtypes and have to be considered in association 
with standard chemotherapy.
RESULTS 
Toxic effects of cytarabine and doxorubicin on 
AML cell lines
To get new insights into the mechanisms underlying 
resistance/susceptibility of AML cells to cytarabine and 
doxorubicin, human AML cells derived from patients 
diagnosed with FAB M2 (HL-60 cell line) and FAB M6 
- erythroleukemia (KG-1 cell line) were exposed to these 
chemotherapeutic agents for 18 h, 24 h and 48 h. Two 
concentrations of cytarabine were used: 10 µM, the most 
commonly used cytarabine concentration for human AML 
cell lines in in vitro assays [43-45] and 1000 µM, to mimic 
chemotherapeutic regimens consisting of high cytarabine 
concentrations [46, 47]. Regarding doxorubicin, the 
half maximal inhibitory concentrations (IC50) were used 
(Table 1). The results showed that cytarabine alone only 
has a drastic impact on AML cells survival for longer 
incubation periods (Figure 1), which is in agreement with 
the commonly used 7 days perfusion therapeutic schemes. 
Moreover, for the treatment time periods analyzed, the 
100-fold increase in the cytarabine concentration had no 
effect on HL-60 or KG-1 cells’ death rate, measured by 
MTS and annexin V/PI assays (Figure 1). Concerning 
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doxorubicin, the concentrations chosen induced around 
40 to 60 % cell death in both cell lines (Figure 1). As 
expectable, exposure of HL-60 and KG-1 cells to the 
combination of the two chemotherapeutic agents for the 
same incubation periods resulted in enhanced loss of cell 
viability in a time-dependent manner, compared to the 
individual treatments (Figure 1).
Of note, the comparison of the cell survival 
percentages obtained by MTS and annexin V/PI assays 
showed a good correlation between both methodologies 
for KG-1 cells (Figure 1C and Figure 1D) but not for HL-
60 cells, particularly in treatment conditions involving 
doxorubicin (Figure 1A and Figure 1B). Previous studies 
Table 1: Concentrations of the drugs - cytarabine (C), 
doxorubicin (D), bortezomib (B), bafilomycin A1 (B 
A1) and compound C (CC) - used in HL-60 and KG-1 
cell lines.
Concentrations (µM)
HL-60 KG-1
Cytarabine (C) 10 or 1000 10 or 1000
Doxorubicin (D) 3 2
Bortezomib (B) 0.02 0.01
Bafilomycin A1 (B A1) 0.01 0.01
Compound C (CC) 2.5 0.5
Figure 1: Toxicity and antitumor effects of cytarabine and doxorubicin on AML cell lines. HL-60 and KG-1 cells were 
incubated for 18 h, 24 h and 48 h with cytarabine and/or doxorubicin. Cellular viability was assessed using the MTS and annexin V/PI 
assays. The results were determined using the non-treated cells as control (100 % of viability) and presented as mean+/-SEM of, at least, 
six biological replicates. One-way ANOVA and Turkey’s Multiple Comparison Test were used to compare the non-treated group with the 
treated groups and within treated groups in the MTS assay. Annexin V/PI data was analyzed by two-way ANOVA and Bonferroni post hoc 
test. Significant differences were obtained between cells untreated vs cells treated and between cells individually treated with cytarabine 
or doxorubicin vs cells treated with the combination of both antileukemia agents. Treatment of cells with different concentrations of 
cytarabine did not present statistically significant differences in cell viability. (A), (C) - HL-60 and KG-1 cells viability determined by MTS 
assay, respectively; (B), (D) - HL-60 and KG-1 cells viability determined by annexin V/PI assay, respectively. Legend: C - cytarabine, 
D - doxorubicin, C+D - cytarabine combined with doxorubicin. Cytarabine: 10 µM or 1000 µM to HL-60 and KG-1 cells; Doxorubicin: 3 
µM to HL-60 cells and 2 µM to KG-1 cells.
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reported that doxorubicin affects mitochondrial activity 
on HL-60 cells [48], which may be responsible for the 
different results obtained with the two methods on this 
cell line and highlight the need to carefully interpret the 
data using MTS to evaluate cell viability in this particular 
condition and the usefulness of using more than one assay 
to evaluate cell viability/survival.
Combination of antileukemia agents induces DNA 
damage and leads to AMPK degradation on AML 
cell lines
To evaluate the impact of antileukemia agents 
(cytarabine and doxorubicin) on DNA damage, we 
assessed the levels of phosphorylated (Ser139) and total 
histone H2AX protein by immunoblotting analysis, an 
important marker of DNA damage response activation 
[49]. The data showed that, in HL-60 cells, the 
combination of the antileukemia agents induced a marked 
increase of H2AX phosphorylation, when compared 
with untreated cells (Figure 2A). In contrast, no major 
alterations of H2AX phosphorylation were observed when 
KG-1 cells were exposed to the same treatment (Figure 
2B). In fact, KG-1 cells displayed high basal levels of 
H2AX phosphorylation (Figure 2B), a phenomenon also 
documented by Boehrer et al. upon exposure of KG-1 
cells to different doses of irradiation [50]. Therefore, to 
further elucidate whether the combination of cytarabine 
and doxorubicin induced DNA damage in KG-1 cells, a 
Terminal dUTP Nick-End Labeling (TUNEL) assay was 
performed. The results clearly showed an increase in the 
percentage of TUNEL positive cells (from about 8 % in 
untreated cells to 65 % in cells treated with chemotherapy 
agents), confirming the induction of DNA damage by 
Figure 2: Combination of antileukemia agents induces DNA damage and leads to AMPK degradation on AML cell 
lines. HL-60 and KG-1 cells were incubated, for 18 h, with cytarabine and doxorubicin. After the treatment period, DNA damage was 
evaluated by immunoblotting analysis of phosphorylated (Ser139) and total H2AX protein levels (A, B). Terminal dUTP Nick-End Labeling 
(TUNEL) staining was performed (green fluorescence) for KG-1 cells and the samples were counter-stained with the DNA dye Propidium 
Iodide (red fluorescence). A minimum of 300 cells were counted per condition and the percentage of TUNEL positive cells was determined. 
The results were obtained by comparing the treated with non-treated cells and presented as mean+/-SEM of three intra-assay replicates. 
Student’s t-test was used to compare the non-treated group with the treated group. ***p <0.001. (C) – Representative images of TUNEL 
assay for KG-1 cells. (D) – Quantification of the TUNEL positive cells. AMPK activation was evaluated by immunoblotting analysis of 
phosphorylated (Thr172) and total AMPK protein levels after 18 h or 48 h of treatment (E, F). Legend: C+D - cytarabine combined with 
doxorubicin. Cytarabine: 10 µM or 1000 µM to HL-60 and KG-1 cells; Doxorubicin: 3 µM to HL-60 cells and 2 µM to KG-1 cells.
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cytarabine and doxorubicin in KG-1 cells (Figure 2C and 
Figure 2D). 
To investigate whether DNA damage response lead 
to AMPK activation [10-12], the levels of phosphorylated 
AMPK (Thr172, the residue phosphorylated in response to 
DNA damage) and total AMPK protein were determined 
by immunoblotting analysis. Our data demonstrated 
that HL-60 cells presented high basal levels of total and 
phosphorylated AMPK, in comparison to KG-1 cells 
(Figure 2E and Figure 2F), which suggests a constitutive 
activation of this pathway in HL-60 cells. 
Interestingly, the cytarabine plus doxorubicin 
treatment resulted in a marked decrease of total AMPK 
protein levels in both cell lines, when compared with 
untreated cells. Of note, such decrease was more evident 
in HL-60 cells (Figure 2E and Figure 2F). According to 
the literature, the AMPK pathway is critically involved in 
the regulation of proliferation and survival of leukemia 
cells [14]. In agreement, our data also suggests AMPK as 
an important survival pathway in AML cells that seems 
to be targeted by the combination of cytarabine and 
doxorubicin.
Doxorubicin induces UPS activation on AML cell 
lines
Recent studies have highlighted that UPS might 
directly or indirectly regulate AMPK activity [51]. To 
elucidate whether UPS was responsible for the observed 
AMPK degradation, under chemotherapeutic agents’ 
exposure (Figure 2E and Figure 2F), UPS activity was 
determined. The results indicated that KG-1 cells present 
a higher basal level of UPS activity, when compared to 
HL-60 cells (Figure 3A). However, in the presence of 
doxorubicin (alone or combined with cytarabine), the 
condition where the AMPK levels are evidently reduced 
(Figure 2E, Figure 2F, Figure 3D and Figure 3E), a 
significant increase in UPS activity was detected in 
both cell lines (Figure 3B and Figure 3C). Of note, the 
Figure 3: Doxorubicin induces UPS activation on AML cell lines. HL-60 and KG-1 (A) UPS basal levels were quantified by the 
measurement of the chymotrypsin-like activity. Additionally, HL-60 (B) and KG-1 (C) cells were incubated, for 18 h, with bortezomib (an 
UPS inhibitor used as negative control), cytarabine and/or doxorubicin. After the treatment period, the UPS activity was quantified using 
the approach referred above. The results were obtained by comparing the treated with non-treated cells and mean+/-SEM of three intra-
assay replicates are shown. One-way ANOVA and Turkey’s Multiple Comparison Test were used to compare the non-treated group with 
the treated groups. *p <0.05; **p <0.01. Additionally, AMPK and S6K (mTORC1 substrate) activation were evaluated by immunoblotting 
analysis of phosphorylated (Thr172) and total AMPK protein levels and phosphorylated (Thr389) and total S6K protein levels, respectively, 
after 18 h of treatment on the HL-60 (D, F) and KG-1 (E, G) cell lines. The arrangement of the AMPK gels is represented separately due 
to the presence of other conditions between the bands of interest. Nevertheless, all conditions were assessed in the same gel. Legend: B – 
bortezomib, C – cytarabine, D – doxorubicin, C+D - cytarabine combined with doxorubicin. Bortezomib: 0.02 µM to HL-60 cells and 0.01 
µM to KG-1 cells; Cytarabine: 1000 µM to HL-60 and KG-1 cells; Doxorubicin: 3 µM to HL-60 cells and 2 µM to KG-1 cells. 
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increased UPS activity was much more pronounced in HL-
60 cells than in KG-1 cells, the cell line that displayed 
the higher basal levels of UPS activity (Figure 3A, Figure 
3B and Figure 3C). Furthermore, the observation of 
less AMPK degradation in KG-1 cells treated with the 
chemotherapeutic agent, when compared with HL-60 
cells in the same conditions, could be associated with 
the lower enhancement of UPS activity observed when 
KG-1 cells are subjected to doxorubicin (Figure 3B and 
Figure 3C). Consistently with the specific degradation of 
AMPK by UPS, our results showed that the combination 
of the antileukemia agents also promoted a decrease of the 
protein levels of the mTOR substrate S6K in both HL-60 
and KG-1 cell lines (Figure 3F and Figure 3G). Altogether, 
the results obtained showed that AML cell lines have 
distinct basal levels of UPS activity and that doxorubicin 
is effectively targeting AMPK for degradation. 
Combined antileukemia agents impact on 
autophagy activity of AML cell lines, particularly 
HL-60 cell line
Given the increased UPS activity observed in 
response to doxorubicin in AML cells (Figure 3B and 
Figure 3C), we investigated the involvement of autophagy, 
the other main proteolytic system, on AML cell’s response 
to chemotherapy. For such purpose, autophagy flux 
was assessed by the immunoblotting analysis of LC3 
processing and of p62 levels (also known as SQSTM1), 
an autophagy substrate [52]. The results showed that both 
cell lines present similar basal autophagic activity levels 
that increase over treatment time (controls from Figure 
4A, Figure 4B, Figure 4D and Figure 4E). Interestingly, 
a similar increase in the AMPK basal levels over the 
course of the experiment was also observed (Figure 2E 
and Figure 2F), which is consistent with the central role of 
Figure 4: Combined antileukemia agents impact on autophagy activity of AML cell lines, particularly in HL-60 cells. 
HL-60 (A, B) and KG-1 (D, E) cells were incubated for 18 h, 24 h (only for KG-1 cells) and 48 h, with cytarabine and doxorubicin and 
after the treatment period, the autophagy activity was assessed using immunoblotting analysis of LC3 processing (I and II) and p62. All 
samples were incubated 2 h before the end of the treatment with bafilomycin A1 (10 nM), in order to block the autophagy flow and to allow 
the accumulation of LC3-II. Densitometric analysis of LC3 protein levels in HL-60 (B) and KG-1 (E) cells was performed using the ratio 
LC3 II/Actin. The bands were quantified in Quantity One® software and the results represent six independent biological replicates. One-
way ANOVA and Turkey’s Multiple Comparison Test were used to compare the all the group conditions.*p<0.05; **p<0.01; ***p<0.001. 
Additionally, LC3 A/B-I/II puncta levels were assessed by immunofluorescence assay after 18 h of treatment. HL-60 (C) and KG-1 (F) 
cells were staining to Goat LC3 anti-Rabbit IgG antibody (green fluorescence) and samples were counter-stained with the DNA dye DAPI 
(blue fluorescence). Representative images of immunofluorescence assay are presented. Bar=20 µm. Legend: C+D - cytarabine combined 
with doxorubicin. Cytarabine: 10 µM and 1000 µM to HL-60 and KG-1 cells; Doxorubicin: 3 µM to HL-60 cells and 2 µM to KG-1 cells.
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the AMPK pathway on the regulation of autophagy [53]. 
As expected, a decrease in p62 levels was also observed 
in a time dependent manner (Figure 4A and Figure 4D). 
The cytarabine/doxorubicin combined treatment caused 
a drastic decrease of autophagic levels in HL-60 cells, 
observed by the clear reduction of LC3 II levels in the 
immunoblotting analysis (Figure 4A and Figure 4B). This 
observation is supported by the evident increase of p62 
levels and decrease of LC3 puncta observed in these cells 
(Figure 4A and Figure 4C). In contrast, for KG-1 cells, the 
combination of the antileukemia agents did not promote 
any major impact on autophagy up to 24 h of treatment 
(Figure 4D and Figure 4F). Nevertheless, a clear reduction 
of both LC3 I and LC3 II levels, as well as of p62 levels, 
was evident after 48 h of treatment with cytarabine and 
doxorubicin (Figure 4D and Figure 4E), a phenomenon 
that was not observed in HL-60 cells (Figure 4A and 
Figure 4B). 
The data showed that the combination of cytarabine 
and doxorubicin is efficient in targeting and inhibiting 
autophagy in HL-60 cells but they can only promote a 
similar effect on KG-1 cells for long time period (48 h, 
Figure 4D and Figure 4E), highlighting that the behavior 
of the proteolytic systems in response to chemotherapy is 
highly dependent on AML subtype.
Modulation of autophagy affects AML cells 
viability
To further clarify the role of autophagy on AML 
cells’ response to chemotherapy, the impact of its 
modulation on the viability of HL-60 and KG-1 cells 
exposed to cytarabine and doxorubicin was determined. 
For such, bafilomycin A1, an autophagy inhibitor, and 
compound C, an efficient pharmacological AMPK 
inhibitor [54] that is also an indirect autophagic activator 
were used. The results showed that addition of bafilomycin 
A1 together with cytarabine and doxorubicin has a 
discrete effect on the viability of AML cells, although 
it is more pronounced on KG-1 cells (Figure 5A and 
Figure 5C). Nevertheless, the combination of compound 
C, an autophagy inducer/activator, with cytarabine and 
doxorubicin promoted a statistically significant increase 
in HL-60 and KG-1 cells’ viability (Figure 5B and Figure 
5D). Although the use of indirect autophagy modulators 
has important limitations, altogether the results clearly 
showed that induction of autophagy promotes cell 
survival. 
Figure 5: Modulation of autophagy affects AML cells viability. HL-60 (A, B) and KG-1 (C, D) cells were incubated, for 18 h, 
with cytarabine and doxorubicin, combined with bafilomycin A1, an autophagy inhibitor and with compound C, an indirect autophagy 
activator (pre-incubation with compound C during 24 h). After the treatment, cells viability was assessed using annexin V/PI assays. The 
results were obtained using the non-treated cells as control (100 %) and mean+/-SEM of, at least, six biological replicates are shown. 
Annexin V/PI data was analyzed by two-way ANOVA and Bonferroni post hoc test. ***p <0.001. Legend: B A1 – bafilomycin A1; CC – 
compound C; C+D - cytarabine combined with doxorubicin. Bafilomycin A1: 10 nM to HL-60 and KG-1 cells; Compound C: 2.5 µM to 
HL-60 cells and 0.5 µM to KG-1 cells; Cytarabine: 1000 µM to HL-60 and KG-1 cells; Doxorubicin: 3 µM to HL-60 cells and 2 µM to 
KG-1 cells.
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DISCUSSION
Cytarabine and doxorubicin are two 
chemotherapeutic agents currently used in the treatment 
of AML [7, 55]. This therapeutic scheme has hardly 
progressed over the last 40 years in spite of its low 
efficiency rates and limited application among old 
individuals and high levels of resistance displayed by 
AML cells to the drugs [5]. Cytarabine and doxorubicin 
are well known inducers of DNA damage [56, 57] and the 
impact of these agents on DNA damage was confirmed 
on HL-60 and KG-1 cells in the conditions described. 
Exposure of both cell lines to the combination of the two 
chemotherapeutic agents induced a clear enhancement 
of H2AX phosphorylation (in HL-60 cells) and a drastic 
increase in the percentage of TUNEL positive cells (in 
KG-1 cells). KG-1 cells were shown to display a high 
constitutive level of H2AX phosphorylation. The role 
of histone H2AX in malignant transformation/cancer 
development is still not totally clear and novel functions 
for phosphorylation of histone H2AX, in addition to DNA 
damage repair, have already been shown, including the 
induction of its phosphorylation through proliferation 
signaling pathways [58], which could occur in the case 
of KG-1 cells.
Although most anticancer therapies rely mainly 
on agents that affect the machinery required for DNA 
replication to induce cell death [59], over the last years, 
different studies have highlighted that chemotherapeutics-
induced DNA damage can also lead to the activation of 
AMPK, a master regulator of cellular energy homeostasis 
[15-17]. Comparison of basal AMPK activity levels 
of the two cell lines studied suggested an association 
between AMPK and the tumorigenicity of the HL-60 
cells. Notably, the cytarabine and doxorubicin treatment 
induced a marked reduction of total AMPK levels that 
is consistent with the increased activity of proteasome. 
This phenomenon is clearly evident in HL-60 cells but 
not in KG-1 cells. Therefore, our data clearly rules out 
the hypothesis of AMPK activation being an AML cell 
survival mechanism activated by the chemotherapeutic 
agents but instead suggests that it could be part of the 
tumorigenic process of HL-60 cells. 
Previous studies reported that UPS could regulate 
AMPK activity by inducing its ubiquitination and 
consequent degradation [51]. Our data is consistent with 
this hypothesis since an increase in UPS activity was 
associated with the AMPK degradation observed on both 
cell lines when exposed to doxorubicin. Of note, the 
lower AMPK degradation in KG-1 cells treated with the 
chemotherapeutic agent, when compared with HL-60 cells 
in the same conditions, could then be associated with the 
lower enhancement of UPS activity observed when KG-1 
cells are subjected to doxorubicin. Moreover, the basal 
UPS activity of KG-1 cells was found to be higher than 
in HL-60 cells in accordance with the higher content of 
KG-1 cells in 20S proteasome previously described [31]. 
Altogether, the data suggests that doxorubicin leads to 
increased UPS activity, resulting in the degradation of 
critical cellular signal transducers and effectors such as 
AMPK and S6K, a downstream target of mTORC1 that in 
turn could also be regulated by the AMPK pathway [60]. 
These findings are highly relevant in the context of the 
antitumoral action of doxorubicin, suggesting that AMPK 
and mTORC1 are important targets of this drug. The 
results also suggest that UPS activity is important on AML 
cell’s response to doxorubicin and that cells with higher 
UPS activity, KG-1 cells, are more resistant to doxorubicin 
(as shown by the higher IC50 value). 
Autophagy is another crucial cellular proteolytic 
system of eukaryotic cells that, together with UPS, plays a 
crucial role on protein catabolism and cellular homeostasis 
[61]. Our findings, when assessing the effect of the two 
chemotherapeutics’ combination in the autophagic activity, 
clearly demonstrated the differential response of the 
two cell lines analyzed. The exposure of HL-60 cells to 
cytarabine and doxorubicin caused an autophagy blockage, 
accompanied by a drastic reduction of the AMPK levels. 
In the KG-1 cell line, however, the combination of these 
drugs did not significantly impact the autophagic activity, 
neither led to AMPK degradation in such a significant 
manner. 
The exact role of autophagy in cancer development/
treatment is still controversial. In AML disorders, recent 
evidence suggests that autophagy acts as a pro-survival 
signal in t(8;21) AML cells [37], however the exact role of 
this process in the different subtypes of this hematologic 
malignancy is still unclear. Our data on autophagy after 
treatment and the modulation of this proteolytic process 
clearly demonstrates the crucial role of autophagy as a 
pro-survival mechanism in AML cells. Nevertheless, 
autophagy seems to be targeted by cytarabine and 
doxorubicin combination in HL-60 cells only. Our 
results imply that, in this cell line, the combination 
of drugs leads to autophagy blockage or autophagy 
players’ and regulators’ degradation. In addition, the 
data clearly highlights the relevance that proteolytic 
systems might have on cells response to chemotherapy 
and the heterogeneity of the response of AML subtypes 
to conventional chemotherapy. In accordance, examples 
of heterogeneity in responses to drugs, leading to the 
activation of different cell death mechanisms, including 
autophagy, have been recently described as being 
dependent on the leukemia subtype, in T-cell acute 
lymphoblastic leukemia [62].
In summary, this study highlights the relevance of 
the proteolytic systems and one of their major regulators, 
AMPK, on AML cells response to chemotherapy, which 
suggests that specific modulators of AMPK activity and 
the autophagy and UPS systems may be promising targets 
for therapeutic intervention in AML. The association of 
such modulators to standard therapeutic strategies could 
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actually allow the reduction of the chemotherapeutics’ 
doses, therefore reducing their toxicity. Identification of 
specific molecular mutations or altered mechanisms and 
appropriate use of this knowledge to the development 
of targeted therapies is recent in the treatment strategy 
of AML. The best studied potential targets are FMS like 
tyrosine kinase 3 (FLT3), RAS/RAF/MEK/ERK and Janus 
kinase (JAK-2) [63]. Based on the findings described 
in this paper, the heterogeneous response of the AML 
subtypes to the therapy commonly used corroborates with 
the strong rationale for the development of different and 
specific therapeutic schemes to apply to AML patients, 
dependent on the molecular abnormalities of each subtype. 
Specifically, our data suggests the AMPK pathway 
and both proteolytic systems might be strong potential 
candidates. Nevertheless, future studies to dissect and 
confirm this data should be performed in primary AML 
samples.
METHODS
Cell culture
The HL-60 (FAB M2) and KG-1 (erythroleukemia 
– FAB M6) cell lines were obtained from the German 
Collection of Microorganisms and Cell cultures (DSMZ® 
- Deutsche Sammlung von Mikroorganismen und 
Zellkulturen - German). Cells were cultured in RPMI 1640 
medium (Biochrom® - Merck Millipore) supplemented 
with 10 % heat-inactivated fetal bovine serum – FBS 
- (Biochrom® - Merck Millipore) and 1 % antibiotic-
antimycotic mixture (Invitrogen®) in a humidified, 37 ºC, 
5 % CO2 atmosphere. Cells in exponential phase of growth 
(passages 5 to 20) were used.
Treatments
Cytarabine, doxorubicin and compound C were 
purchased from Sigma-Aldrich® and were dissolved in 
dH2O. Bafilomycin A1 was also purchased from Sigma-
Aldrich® but prepared in DMSO. Bortezomib was 
obtained from Santa Cruz® and was prepared in dH2O. The 
concentrations used for each drug are described in Table 1.
Measurement of cell survival – MTS assay
Cell viability of HL-60 and KG-1 cells was assessed 
using the Cell Titer 96 Aqueous One Solution Cell 
Proliferation Assay (MTS), acquired from Promega®. HL-
60 and KG-1 cell lines were plated at 350.000 cells/700 μl 
per well and exposed to the different drug combinations. 
The number of viable cells in culture was determined at 
18 h, 24 h and 48 h of treatment exposure (or control). 
100 μl of the cells’ suspension was then transferred to 96-
well plates and 10 µL of MTS solution (1.90 mg/ml) were 
added to each well followed by incubation in a humidified, 
37 ºC, 5 % CO2 atmosphere. Absorbance at 490 nm was 
recorded after 2 h of incubation. Blank controls detecting 
cell-free RPMI + drug and RPMI absorbances were 
performed in parallel. At least six biological replicates 
were prepared. 
Measurement of cell viability – Annexin V and PI 
analysis
HL-60 and KG-1 cell lines were plated at 350.000 
cells/700 μl per well and collected at 18 h, 24 h and 48 h 
of treatment (or control). The cells were then washed with 
800 µl of PBS and 100 µL of binding buffer was added 
to each sample. An incubation with 5 µL of annexin V 
(BD Biosciences®) and with 10 µL of Propidium iodide 
(PI) at 50 µg/ml (Invitrogen®) was performed for 15 min 
at room temperature, in the dark, and 200 µL of binding 
buffer were added once again. PI signals were measured 
using the FACS LSRII flow cytometer (BD Biosciences®) 
with a 488 nm excitation laser. The annexin V signal was 
collected through a 488 nm blocking filter, a 550 nm 
long-pass dichroic with a 525 nm band pass. Signals from 
10.000 cells/sample were captured and FACS Diva was 
used as the acquisition software. Results analysis was 
performed using the FlowJo 7.6 (Tree Star®) software. The 
results represent, at least, six biological replicates.
Western blot analysis 
Protein extraction was performed with 50 µL of 
lysis buffer (1 % NP-40, 500 mM Tris HCL, 2.5 M NaCl, 
20 mM EDTA, Phosphatase and Protease inhibitors - from 
Roche® -, at pH 7.2) 18 h, 24 h and 48 h after HL-60 and 
KG-1 cell lines were exposed to treatment (or control). 20 
µg of the total protein were resolved in a 12 % SDS gel and 
transferred to a Nitrocellulose membrane for 7 or 15 min 
in Trans-Blot Turbo® transfer system. Membranes were 
blocked in phosphate-buffered saline (PBS) with 0.1 % 
tween 20 (PBS-T) containing 5 % skim milk Molico
®
 and 
afterwards incubated overnight at 4 ºC, with the polyclonal 
primary antibodies at 1:1000 in 1 % BSA (Bovine Serum 
Albumin) - Rabbit anti-histone H2AX Antibody; Rabbit 
anti-phospho-histone H2AX (Ser139) Antibody; Rabbit 
anti-AMPKα Antibody; Rabbit anti-phospho-AMPKα 
(Thr172) Antibody; Rabbit anti-p70 S6K Antibody; 
Rabbit anti-phospho-p70 S6K Antibody (Thr389); Rabbit 
anti-LC3A/B Antibody (all from Cell-Signaling®); Rabbit 
anti-p62 Antibody (Sigma-Aldrich®) and Mouse anti-Actin 
antibody (Millipore®). After washing with tris-buffered 
saline-tween (TBS-T), membranes were incubated with 
the corresponding secondary antibodies - IgG anti-Mouse 
for Actin (Chemicon International®) and IgG anti-Rabbit 
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for all the others (Cell-Signaling®), at 1:5000 in 1 % skim 
milk for 2 h at room temperature. Protein levels were 
detected after incubation with SuperSignal® West Femto 
Maximum Sensitivity Substrate (Thermo Scientific®) 
or Clarity® Western ECL Substrate (Bio-Rad®). Digital 
images of the western blotting were obtained in a 
‘ChemiDoc XRS System’ (Bio-Rad®) with Quantity One 
(Bio-Rad®) software. At least, six independent biological 
replicates were performed.
TUNEL analysis
The cytospin technique was performed to fixe 
50.000 HL-60 or KG-1 cells/plate, after 18 h of treatment 
(or control). Cells were fixed (PFA 4 %), washed and 
permeabilized with 0.1 % Triton X-100 in 0.1 % sodium 
citrate for 7 min on ice. The Terminal dUTP Nick-End 
Labeling (TUNEL) analysis was performed using the “In 
Situ Cell Death Detection” kit, Fluorescein (Roche®) 
following the manufacter‘s instructions. Cells were also 
stained with PI (Invitrogen®), binding DNA regions. 
Three independent biological replicates were used. An 
epifluorescence microscope (BX61 microscope with an 
Olympus DP70 camera) was used for slide visualization 
and then the images were analyzed with ImageJ® Software 
(National Institutes of Health).
Proteolytic activity of Ubiquitin-proteasome 
system (UPS)
“Proteasom-GloTM Cell-Based Assays” (Promega®) 
was used to measure the proteolytic activity of the 
UPS. It comprises a luminescent assay that measures 
the chymotrypsin-like activity associated with the 
proteasome complex in cells [64]. Chymotrypsin-like 
(SUC-LLVY-Glo subs) was chosen as a proteasome 
subtract. Proteasome-Glo™ Cell-Based Reagents were 
both prepared and equilibrated at 22°C for 30 min before 
use. The luminescence was measured in a luminometer 
“Fluoroskan Ascent FL” by ThermoScientific. 350.000 
cells (HL-60 or KG-1) were diluted in 700 µl of RPMI 
1640 medium containing 10 % FBS and 1 % antibiotic 
with treatments and equilibrated in an incubator with 
controlled % of CO2 (5 %), temperature (37 °C) and 
humidity. After 18 h of treatment (or control), 25.000 
cells were plated in a 96-well opaque plate, comprising a 
volume of 100 µl. This was combined with “Proteasom-
GloTM Cell-Based Assays” (100 µl), the assay plate was 
equilibrated at 22 °C, and after incubation during 5 to 30 
min, a luminescent signal was obtained. 
Immunofluorescence staining
HL-60 or KG-1 cells (30.000 cells/plate) were 
resuspended in PBS, after 18 h under treatment, and were 
fixed in a slide by cytospin technic. After this, fixation 
was performed in PFA 2 %. Cells were then washed, 
permeabilized and blocked with 4 % BSA in PBS 0.05 
% Tween. Incubation with primary antibody, Rabbit 
anti-mouse LC3 A/B (Cell-Signaling®), was executed 
overnight, at 4 °C. Goat anti-Rabbit IgG Alexa Fluor 488 
- green-fluorescent dye - (Molecular Probes®) was used 
as secondary antibody. Cells were also stained with DAPI 
(4’,6-diamidino-2-phenylindole) that binds regions in 
DNA, marking the cell nuclei. Three biological replicates 
were used. An epifluorescence microscope (BX61 
microscope with an Olympus DP70 camera) was used to 
slide visualization and then images were analyzed with 
ImageJ® Software (National Institutes of Health).
Statistical analysis
All data is reported as the mean ± standard error 
of the mean (SEM). Statistical analysis was performed 
using the student’s t-test and the one-way ANOVA test. 
Multiple comparison test was used as Post-Hoc test to 
denote significant differences between groups untreated, 
groups subjected to drugs and respective combinations. 
Additionally, the two-away ANOVA and Bonferroni post 
hoc tests were also used to compare the non-treated group 
with the treated groups and respective combinations for 
annexin V/PI approaches. A p-value lower than 0.05 was 
assumed to denote a significant difference.
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